New coronavirus cases continue to spike around the globe, leading health and government officials in Austin, Texas, to extend stay-at-home orders, while Beijing announces it will close down schools and certain sectors of the economy again. Yahoo Finance’s Anjalee Khemlani breaks down the latest news about the coronavirus on The Final Round. ...
Amarin (AMRN) is seriously undervalued, according to Cantor analyst Louise Chen.On Monday, the drug maker presented encouraging new data from the REDUCE-IT study. After taking 4g a day of Vascepa, Amarin’s high triglycerides treatment, diabetes patients experienced a 23% drop in both first and total primary composite major adverse cardiovascular events. Chen thinks this data underscores Vascepa's “continuing commercial success and future potential.”“We believe the news is important because it is the first time that data specific to the diabetes population has been presented. Included for example was that in the diabetic patients treated in REDUCE-IT more than half of such patients were already on two or more drugs for diabetes and over 90% were on at least one such medicine. This emphasized that the Vascepa results were incremental to the lowering of A1C and other impacts of such medicines,” the analyst said.Sales of Vascepa, Amarin’s only product, have been hit...
Novavax, Inc. (NASDAQ: NVAX), which is also considered one of the frontrunners in the coronavirus vaccine, announced a few additions to its executive team.What Happened: The company said Wednesday it has appointed AstraZeneca plc (NYSE: AZN) veteran Filip Dubovsky as SVP and Chief Medical Officer, overseeing its medical and clinical affairs and related activities.Dubovsky has more than 20 years of experience in infectious diseases and was overseeing clinical development of early and late-stage infectious disease and vaccine assets at AstraZeneca's biologics arm MedImmune.The company also announced the appointment of Silvia Taylor, as SVP, Investor Relations and Corporate Affairs.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Why It Matters: Novavax reported in late March positive Phase 3 results for its influenza vaccine candidate NanoFlu.In late May, the company commenced human studies of its SARS-CoV-2 vaccine candidate, NVX-CoV2373. It also...
In this article you are going to find out whether hedge funds think Fastly, Inc. (NYSE:FSLY) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among […]...
